DE602005010436D1 - P75ntr-screeningtest zur identifizierung von modulatoren der apoptose - Google Patents

P75ntr-screeningtest zur identifizierung von modulatoren der apoptose

Info

Publication number
DE602005010436D1
DE602005010436D1 DE602005010436T DE602005010436T DE602005010436D1 DE 602005010436 D1 DE602005010436 D1 DE 602005010436D1 DE 602005010436 T DE602005010436 T DE 602005010436T DE 602005010436 T DE602005010436 T DE 602005010436T DE 602005010436 D1 DE602005010436 D1 DE 602005010436D1
Authority
DE
Germany
Prior art keywords
apoptosis
p75ntr
modulators
identification
screening test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005010436T
Other languages
English (en)
Inventor
Wouter David Bruinzeel
Miroslav Cik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE602005010436D1 publication Critical patent/DE602005010436D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602005010436T 2004-07-14 2005-07-11 P75ntr-screeningtest zur identifizierung von modulatoren der apoptose Active DE602005010436D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04103368 2004-07-14
US58855104P 2004-07-16 2004-07-16
PCT/EP2005/053304 WO2006005740A2 (en) 2004-07-14 2005-07-11 P75ntr screening assay for indentifying modulators of apoptosis

Publications (1)

Publication Number Publication Date
DE602005010436D1 true DE602005010436D1 (de) 2008-11-27

Family

ID=39243741

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005010436T Active DE602005010436D1 (de) 2004-07-14 2005-07-11 P75ntr-screeningtest zur identifizierung von modulatoren der apoptose

Country Status (9)

Country Link
US (1) US8637464B2 (de)
EP (1) EP1771572B1 (de)
AT (1) ATE411393T1 (de)
AU (1) AU2005261721B2 (de)
CA (1) CA2571130C (de)
DE (1) DE602005010436D1 (de)
DK (1) DK1771572T3 (de)
ES (1) ES2315889T3 (de)
WO (1) WO2006005740A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011163241A2 (en) * 2010-06-21 2011-12-29 Georgetown University Neuroprotective compounds
WO2014049556A2 (en) * 2012-09-28 2014-04-03 The University Of Queensland Neurotrophin-tyrosine kinase receptor signaling
EP2950095B1 (de) * 2014-05-28 2018-08-29 Technische Universität Dresden Zellenbasierte Test- und Screeningverfahren auf Modulatoren von p75NTR-Signalisierung
IT202000007720A1 (it) * 2020-04-10 2021-10-10 Alessandra Marconi Peptidi e loro usi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU689248B2 (en) * 1994-04-11 1998-03-26 Nexins Research B.V. A method for detecting and/or optionally quantifying and/or separating apoptotic cells in or from a sample
ATE408688T1 (de) * 1998-10-06 2008-10-15 Univ Queensland Polypeptide zur modulierung des überlebens von zellen
FR2801320B1 (fr) * 1999-11-19 2002-02-15 Inst Nat Sante Rech Med Procede d'evaluation de la genotoxicite d'un compose
US6881719B2 (en) 2000-01-18 2005-04-19 Mcgill University β-turn peptidomimetic cyclic compounds

Also Published As

Publication number Publication date
ES2315889T3 (es) 2009-04-01
CA2571130C (en) 2014-08-19
EP1771572B1 (de) 2008-10-15
CA2571130A1 (en) 2006-01-19
US8637464B2 (en) 2014-01-28
DK1771572T3 (da) 2009-02-16
WO2006005740A3 (en) 2006-06-29
WO2006005740A2 (en) 2006-01-19
EP1771572A2 (de) 2007-04-11
US20080064036A1 (en) 2008-03-13
AU2005261721B2 (en) 2011-02-24
ATE411393T1 (de) 2008-10-15
AU2005261721A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
WO2002087306A3 (en) High throughput cell-based assay for monitoring sodium channel activity and discovery of salty taste modulating compounds
DE69430573T2 (de) Test und reagentien zur identifizierung von antiproliferierenden stoffen
ATE269974T1 (de) Identifizierung und charakterisierung von interagierenden molekülen mittels automatisierter interagierender paarung
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
ATE382060T1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
DE602005010436D1 (de) P75ntr-screeningtest zur identifizierung von modulatoren der apoptose
DE60038127D1 (de) Methoden und syteme zur überwachung intrazellulärer bindereaktionen
NZ591668A (en) Isolation and identification of glycosaminoglycans
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
DE69841434D1 (de) VERWENDUNG VON FVIIa ODER FVIIAi ZUR BEHANDLUNG VON ENDOTHELIALER FEHLFUNKTION BZW ZUR INHIBIERUNG DER ANGIOGENESE
DE60216245D1 (de) Funktionelles oberflächendisplay von polypeptiden
Li et al. Polycystin-1 interacts with inositol 1, 4, 5-trisphosphate receptor to modulate intracellular Ca2+ signaling with implications for polycystic kidney disease
Li et al. Development of human in vitro brain-blood barrier model from induced pluripotent stem cell-derived endothelial cells to predict the in vivo permeability of drugs
ATE254660T1 (de) Methode zur markierung von eukaryotischen zellen mittels verwendung von rezeptoren der zelloberfläche als marker
MXPA04001287A (es) Ensayo de receptor unido a proteina g.
ATE354635T1 (de) Substrat und verfahren zum messen elektrophysiologischer eigenschaften von zellmembranen
ATE404692T1 (de) Screening-verfahren zur identifizierung von tau- protein modulierenden substanzen.
MXPA03011898A (es) Ensayo de seleccion in vitro para ?- secretasa.
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
DE602004026445D1 (de) Verwendung von cardiotrophin zur modulation der stammzellenproliferation
Kikkawa et al. Maintenance of hepatic differentiation by hepatocyte attachment peptides derived from laminin chains
ATE469238T1 (de) Verwendung von fluor-nmr zum screening mit hohem durchsatz
WO2006055959A3 (en) Pf4 pharmacophores and their uses
UY25687A1 (es) Metodo para identificar sustancias para el tratamiento de trastornos mediados por c-jun
González-Aragón et al. ES936 stimulates DNA synthesis in HeLa cells independently on NAD (P) H: quinone oxidoreductase 1 inhibition, through a mechanism involving p38 MAPK

Legal Events

Date Code Title Description
8364 No opposition during term of opposition